Otsuka Pakistan Past Earnings Performance
Past criteria checks 2/6
Otsuka Pakistan has been growing earnings at an average annual rate of 19.3%, while the Pharmaceuticals industry saw earnings growing at 6.3% annually. Revenues have been growing at an average rate of 10.1% per year. Otsuka Pakistan's return on equity is 12%, and it has net margins of 3%.
Key information
19.3%
Earnings growth rate
19.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 20.2% |
| Revenue growth rate | 10.1% |
| Return on equity | 12.0% |
| Net Margin | 3.0% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Otsuka Pakistan makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,828 | 84 | 499 | 0 |
| 31 Dec 23 | 3,014 | 37 | 493 | 0 |
| 30 Sep 23 | 3,127 | 51 | 496 | 0 |
| 30 Jun 23 | 3,035 | -7 | 497 | 0 |
| 31 Mar 23 | 3,104 | -40 | 504 | 0 |
| 31 Dec 22 | 3,013 | 87 | 496 | 0 |
| 30 Sep 22 | 2,829 | 136 | 495 | 0 |
| 30 Jun 22 | 2,852 | 232 | 483 | 0 |
| 31 Mar 22 | 2,894 | 397 | 439 | 0 |
| 31 Dec 21 | 2,822 | 423 | 420 | 0 |
| 30 Sep 21 | 2,661 | 418 | 396 | 0 |
| 30 Jun 21 | 2,546 | 386 | 385 | 0 |
| 31 Mar 21 | 2,392 | 235 | 370 | 0 |
| 31 Dec 20 | 2,308 | 145 | 360 | 0 |
| 30 Sep 20 | 2,304 | 109 | 360 | 0 |
| 30 Jun 20 | 2,227 | 91 | 365 | 0 |
| 31 Mar 20 | 2,124 | -49 | 373 | 0 |
| 31 Dec 19 | 2,094 | -49 | 373 | 0 |
| 30 Sep 19 | 1,977 | -153 | 365 | 0 |
| 30 Jun 19 | 1,885 | -175 | 348 | 0 |
| 31 Mar 19 | 1,911 | -49 | 358 | 0 |
| 31 Dec 18 | 1,872 | -46 | 349 | 0 |
| 30 Sep 18 | 1,805 | 32 | 334 | 0 |
| 30 Jun 18 | 1,869 | 65 | 321 | 0 |
| 31 Mar 18 | 1,888 | 65 | 299 | 0 |
| 31 Dec 17 | 1,884 | 82 | 291 | 0 |
| 30 Sep 17 | 1,907 | 138 | 296 | 0 |
| 30 Jun 17 | 1,830 | 110 | 289 | 0 |
| 31 Mar 17 | 1,755 | 95 | 286 | 0 |
| 31 Dec 16 | 1,726 | 29 | 279 | 0 |
| 30 Sep 16 | 1,634 | -58 | 262 | 0 |
| 30 Jun 16 | 1,551 | -112 | 256 | 0 |
| 31 Mar 16 | 1,482 | -173 | 254 | 0 |
| 31 Dec 15 | 1,447 | -164 | 256 | 0 |
| 30 Sep 15 | 1,424 | -132 | 256 | 0 |
| 30 Jun 15 | 1,452 | -146 | 254 | 0 |
| 31 Mar 15 | 1,328 | -130 | 238 | 0 |
| 31 Dec 14 | 1,175 | -170 | 230 | 0 |
| 30 Sep 14 | 1,134 | -219 | 221 | 0 |
| 30 Jun 14 | 1,078 | -200 | 221 | 0 |
| 31 Mar 14 | 1,125 | -190 | 225 | 0 |
| 31 Dec 13 | 1,169 | -116 | 231 | 0 |
| 30 Sep 13 | 1,232 | -60 | 238 | 0 |
Quality Earnings: OTSU has a large one-off gain of PKR17.6M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: OTSU became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OTSU has become profitable over the past 5 years, growing earnings by 19.3% per year.
Accelerating Growth: OTSU has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: OTSU has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).
Return on Equity
High ROE: OTSU's Return on Equity (12%) is considered low.